|
Volumn 91, Issue 4, 2001, Pages 550-554
|
Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody β-glucuronidase conjugate
|
Author keywords
ADEPT; Anthracyclines; Antibody directed enzyme prodrug therapy; Selective chemotherapy
|
Indexed keywords
BETA GLUCURONIDASE;
CARBAMIC ACID DERIVATIVE;
CELL ADHESION MOLECULE;
DOXORUBICIN;
MONOCLONAL ANTIBODY;
N [4 DOXORUBICIN N CARBONYL(OXYMETHY)PHENYL] O BETA GLUCURONYLCARBAMATE;
PRODRUG;
UNCLASSIFIED DRUG;
ANIMAL CELL;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ANTIBODY DIRECTED ENZYME PRODRUG THERAPY;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
CANCER CELL;
CANCER INHIBITION;
CANCER REGRESSION;
CONJUGATE;
CONTROLLED STUDY;
DOSE RESPONSE;
DRUG EFFICACY;
ENZYME LOCALIZATION;
HUMAN;
HUMAN CELL;
MOUSE;
NONHUMAN;
OVARY CARCINOMA;
PRIORITY JOURNAL;
TREATMENT OUTCOME;
TUMOR NECROSIS;
ANIMALS;
ANTIBIOTICS, ANTINEOPLASTIC;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
BODY WEIGHT;
CELL DIVISION;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DOXORUBICIN;
FEMALE;
GLUCURONIC ACIDS;
GLUCURONIDASE;
HUMANS;
MAXIMUM TOLERATED DOSE;
MEMBRANE GLYCOPROTEINS;
MICE;
MICE, NUDE;
MODELS, CHEMICAL;
NECROSIS;
NEOPLASM TRANSPLANTATION;
NEOPLASMS;
OVARIAN NEOPLASMS;
PRODRUGS;
TIME FACTORS;
TUMOR CELLS, CULTURED;
|
EID: 0035866038
PISSN: 00207136
EISSN: None
Source Type: Journal
DOI: 10.1002/1097-0215(200002)9999:9999<::AID-IJC1075>3.0.CO;2-L Document Type: Article |
Times cited : (56)
|
References (28)
|